IMMUNITYBIO, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-351.4M | $-413.6M | $-583.2M | $-416.6M | $-346.8M | $-221.9M | $-157.8M | $-96.2M |
| Depreciation & Amortization | $15.5M | $17.6M | $18.5M | $18.3M | $14.2M | $12.7M | $14.0M | $9.6M |
| Depreciation | $13.4M | $15.5M | $16.5M | $16.3M | $14.2M | $12.7M | $8.4M | $7.3M |
| Amortization | — | $2.0M | $2.0M | $1.9M | — | — | $600.0K | $2.3M |
| Stock-Based Compensation | $36.8M | $34.4M | $49.2M | $40.2M | $57.2M | $2.2M | $3.4M | $23.4M |
| Net Cash from Operating Activities | $-304.9M | $-391.2M | $-366.8M | $-337.5M | $-274.4M | $-171.7M | $-152.1M | $-63.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $3.8M | $6.9M | $30.6M | $78.2M | $33.6M | $1.7M | $4.3M | $13.1M |
| Business Acquisitions | $0 | $1.0M | $0 | $0 | — | — | — | — |
| Net Cash from Investing Activities | $-149.8M | $-12.2M | $-30.5M | $27.3M | $-84.9M | $-19.8M | $18.6M | $57.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | $0 | $0 | $2.5M | $228.0K |
| Net Cash from Financing Activities | $400.2M | $281.6M | $558.3M | $233.6M | $505.4M | $150.7M | $114.3M | $-771.0K |
| Net Change in Cash | $-54.5M | $-121.9M | $160.8M | $-76.3M | $146.2M | $-40.9M | $-19.3M | — |
| Free Cash Flow | $-308.8M | $-398.1M | $-397.3M | $-415.7M | $-308.0M | $-173.4M | $-156.4M | $-76.5M |